Top Back to top

A multi-centre, multinational, prospective observational registry to collect safety and outcome data in patients diagnosed with severe hepatic veno-occlusive disease (VOD) following hematopoietic stem cell transplantation (HSCT) and treated with Defitelio®

Study number:
DF VOD-2013-03-REG
Short title:
Study status:
Deadline for data collection:
Study design:
Prospective, multinational study - 1 cohort (under defibrotide)
Primary objective:
The main objective of the registry is to assess the incidence rate of specific serious adverse events (SAEs) of interest (including fatalities) in patients with severe hepatic VOD post-HSCT treated with Defitelio®
Key inclusion criteria:
- Any consenting patient with a diagnosis of severe VOD post-HSCT (treated with defibrotide)
- Any consenting patient receiving defibrotide for any other condition (VOD Prophylaxis, non-severe VOD…) in HSCT context
United Kingdom
Principal investigator:
Pr Mohamad Mohty
Principal investigator email:
EBMT Study coordinator:
Jessica Lemaitre
Study coordinator email: